← Back
Data updated: Mar 29, 2026
BE PHARMS
Infectious DiseaseDermatologyCardiovascular
Generics
BE PHARMS is a generic drug manufacturer focused on Infectious Disease, Dermatology, Cardiovascular.
2019
Since
9
Drugs
-
Trials
91
Approved (2yr)
Key Drugs
No active drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
HEPARIN SODIUM 2026-02-20
Labeling
HEPARIN SODIUM 2026-02-20
Labeling
DAPTOMYCIN 2026-01-30
Labeling
DAPTOMYCIN 2026-01-26
Labeling
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2026-01-07
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2025-11-25
Labeling
NEOSTIGMINE METHYLSULFATE 2025-10-24
Labeling
PANTOPRAZOLE SODIUM 2025-10-15
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 25%
1 drugs
Dermatology 25%
1 drugs
Cardiovascular 25%
1 drugs
Respiratory 25%
1 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
APOTHECON specialty
Infectious Disease, Dermatology, Cardiovascular, Respiratory
Baxter specialty
Infectious Disease, Cardiovascular, Dermatology
LEDERLE big-pharma
Infectious Disease, Cardiovascular, Dermatology, Respiratory
B BRAUN specialty
Infectious Disease, Dermatology, Cardiovascular
COSETTE other
Cardiovascular, Dermatology, Infectious Disease
Active (6)
Discontinued (3)
Company Info
- First Approval
- 2019-05-13
- Latest
- 2025-02-04
- Applications
- 11